Evercore ISI Issues Positive Forecast for Bio-Techne (NASDAQ:TECH) Stock Price

Bio-Techne (NASDAQ:TECH) had its price target hoisted by equities researchers at Evercore ISI from $62.00 to $68.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm currently has an “in-line” rating on the biotechnology company’s stock. Evercore ISI’s target price would indicate a potential upside of 2.54% from the stock’s current price.

Other equities analysts have also recently issued research reports about the stock. Robert W. Baird set a $70.00 price objective on shares of Bio-Techne in a research note on Thursday. UBS Group reaffirmed a “buy” rating and issued a $79.00 price objective (up previously from $70.00) on shares of Bio-Techne in a research note on Thursday. TD Cowen reiterated a “buy” rating and issued a $80.00 price target (up from $70.00) on shares of Bio-Techne in a research report on Thursday. Citigroup reissued a “buy” rating on shares of Bio-Techne in a report on Wednesday. Finally, Argus boosted their target price on shares of Bio-Techne from $65.00 to $68.00 and gave the stock a “buy” rating in a report on Thursday, November 20th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, four have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $72.86.

Bio-Techne Stock Performance

Bio-Techne stock traded down $2.36 during midday trading on Thursday, reaching $66.31. 1,071,202 shares of the company traded hands, compared to its average volume of 2,513,746. The company has a debt-to-equity ratio of 0.15, a current ratio of 4.22 and a quick ratio of 2.81. Bio-Techne has a 12 month low of $46.01 and a 12 month high of $77.03. The firm has a market capitalization of $10.33 billion, a price-to-earnings ratio of 135.41, a price-to-earnings-growth ratio of 4.46 and a beta of 1.48. The business has a 50 day moving average of $63.23 and a two-hundred day moving average of $59.21.

Bio-Techne (NASDAQ:TECH) last announced its earnings results on Wednesday, February 4th. The biotechnology company reported $0.46 earnings per share for the quarter, beating analysts’ consensus estimates of $0.43 by $0.03. The business had revenue of $295.88 million during the quarter, compared to analyst estimates of $290.20 million. Bio-Techne had a net margin of 6.41% and a return on equity of 13.59%. The company’s quarterly revenue was down .4% compared to the same quarter last year. During the same period in the previous year, the business earned $0.42 EPS. As a group, research analysts predict that Bio-Techne will post 1.67 earnings per share for the current year.

Hedge Funds Weigh In On Bio-Techne

Large investors have recently made changes to their positions in the company. Blue Trust Inc. raised its holdings in shares of Bio-Techne by 109.7% in the third quarter. Blue Trust Inc. now owns 453 shares of the biotechnology company’s stock worth $25,000 after buying an additional 237 shares during the period. Danske Bank A S purchased a new stake in Bio-Techne in the 4th quarter valued at about $29,000. eCIO Inc. purchased a new position in shares of Bio-Techne during the fourth quarter worth approximately $30,000. Allworth Financial LP raised its stake in shares of Bio-Techne by 68.1% during the second quarter. Allworth Financial LP now owns 612 shares of the biotechnology company’s stock valued at $31,000 after acquiring an additional 248 shares in the last quarter. Finally, Measured Wealth Private Client Group LLC bought a new position in Bio-Techne in the third quarter worth approximately $32,000. 98.95% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Bio-Techne

Here are the key news stories impacting Bio-Techne this week:

• Positive Sentiment: Q2 results topped estimates: adjusted EPS beat and reported revenue modestly exceeded Street forecasts; operating margin expanded ~244 bps, driven by cost leverage. This helped show profitability resilience despite revenue pressure. Bio-Techne Releases Second Quarter Fiscal 2026 Results
• Positive Sentiment: Management signaled mid‑single‑digit underlying growth for FY2026 with planned margin expansion and a normalization in the cell therapy business — a constructive outlook for margins and recovery in that end market. Bio‑Techne signals mid‑single‑digit underlying growth for fiscal 2026, with margin expansion and cell therapy normalization ahead
• Positive Sentiment: Analyst support: Citi’s Patrick Donnelly kept a Buy rating with an $80 price target, citing near‑term resilience and margin leverage that could support accelerating growth into 2027. Bio‑Techne: Near‑Term Resilience and Margin Expansion Support Accelerating Growth and Buy Rating Into 2027
• Neutral Sentiment: Board declared a quarterly dividend of $0.08 per share (payable Feb 27), a small income signal but immaterial to valuation dynamics. Bio‑Techne Declares Dividend
• Neutral Sentiment: Earnings call/transcript published for investors wanting details on segment performance and management commentary. Bio‑Techne Q2 2026 Earnings Call Transcript
• Negative Sentiment: Top‑line softness: reported organic sales were flat and company revenue was down ~0.4% year‑over‑year — investors focused on growth may view this as a disappointment versus higher expectations for acceleration.
• Negative Sentiment: Valuation vs. growth: the stock trades at a high P/E and PEG, so a modest guidance (mid‑single digits) and flat organic sales raise concerns that upside to the valuation could be limited absent a clearer revenue rebound.

About Bio-Techne

Bio-Techne Corporation (NASDAQ:TECH) is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.

Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.